Transcatheter Interatrial Septal Defect Closure in a Large Cohort: Midterm Follow-up Results

Basit Öğe Kaydı
dc.authoridOto, Sibel/0000-0003-0171-4200
dc.authoridCanpolat, Ugur/0000-0002-4250-1706
dc.authoridSahiner, Mehmet Levent/0000-0002-0985-3144
dc.contributor.authorAytemir, Kudret
dc.contributor.authorOto, Ali
dc.contributor.authorOzkutlu, Suheyla
dc.contributor.authorCanpolat, Ugur
dc.contributor.authorKaya, Ergun Baris
dc.contributor.authorYorgun, Hikmet
dc.contributor.authorSahiner, Levent
dc.date.accessioned2025-03-23T19:32:02Z
dc.date.available2025-03-23T19:32:02Z
dc.date.issued2013
dc.departmentSinop Üniversitesi
dc.description.abstractObjectivesWe evaluated immediate and midterm results of transcatheter closure of atrial septal defects (ASDs) and patent foramen ovale (PFO) using various closure devices. Materials and MethodsThe study included four hundred fourteen patients (one hundred eighty-two men, two hundred thirty-two women; mean age 39 12.3 years; range 17-67 years) who underwent transcatheter closure of secundum ASD (n = 193) or PFO (n = 221). All the patients were evaluated by transthoracic echocardiography and transesophageal echocardiography before the procedure. Transcatheter closure was performed by using Amplatzer (n = 184), Occlutech Figulla (n = 209), or BioSTAR (n = 21) devices. Closure of ASDs was performed under general anesthesia with transesophageal echocardiography guidance, and closure of PFOs was performed under local anesthesia with transthoracic echocardiography guidance. Follow-up controls were at 1, 6, and 12 months and annually thereafter. The median follow-up periods of ASD and PFO patients were 43 and 30 months. ResultsThe mean device size was 19.3 +/- 6.2mm for ASD patients and 24.6 +/- 2.6mm for PFO patients. The mean procedural and fluoroscopy times were 22.3 +/- 4.7 and 4.1 +/- 1.9 minutes for ASD closure and 12.4 +/- 3.2 and 3.1 +/- 1.2 minutes for PFO closure, respectively. Procedural device embolization occurred in only two patients (0.48%). During follow-up, recurrent embolic events occurred in four patients (1.8%) after PFO closure, and no residual shunts were seen after ASD closure. Device thrombosis developed in two ASD patients during the procedure and in one PFO patient at 12th month of the follow-up (0.72%). ConclusionTranscatheter closure of PFOs and secundum-type ASDs using the Amplatzer, Occlutech Figulla, and BioSTAR devices is an efficacious and safe therapeutic option.
dc.identifier.doi10.1111/chd.12057
dc.identifier.endpage427
dc.identifier.issn1747-079X
dc.identifier.issn1747-0803
dc.identifier.issue5
dc.identifier.pmid23601507
dc.identifier.scopusqualityQ4
dc.identifier.startpage418
dc.identifier.urihttps://doi.org/10.1111/chd.12057
dc.identifier.urihttps://hdl.handle.net/11486/5391
dc.identifier.volume8
dc.identifier.wosWOS:000324924600015
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherTech Science Press
dc.relation.ispartofCongenital Heart Disease
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250323
dc.subjectAtrial Septal Defect
dc.subjectPatent Foramen Ovale
dc.subjectOccluder Device
dc.titleTranscatheter Interatrial Septal Defect Closure in a Large Cohort: Midterm Follow-up Results
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu